Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, L. Green, Monique Topp et al.|Nature Communications|2018Cited by 299
Prognostic gene expression signature for high-grade serous ovarian cancerJoshua Millstein, Scott D. Brown, Timothy Budden et al.|Annals of Oncology|2020Cited by 173
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal MalignanciesKevin E. Fisher, Michael R. Rossi, Linsheng Zhang et al.|Journal of Molecular Diagnostics|2016Cited by 69
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nešić, Harold C. Sullivan, John J. Krais et al.|Molecular Cancer|2024Cited by 28
The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipientsRonald F. Parsons, Howard M. Gebel, Annette M. Jackson et al.|American Journal of Transplantation|2019Cited by 25